Achaogen (AKAO) Given Average Recommendation of “Buy” by Brokerages

Shares of Achaogen (NASDAQ:AKAO) have been assigned an average rating of “Buy” from the twelve analysts that are covering the stock, MarketBeat.com reports. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $21.17.

A number of equities analysts have commented on AKAO shares. HC Wainwright boosted their price target on shares of Achaogen from $25.00 to $31.00 and gave the company a “buy” rating in a research report on Wednesday, February 7th. ValuEngine upgraded shares of Achaogen from a “sell” rating to a “hold” rating in a research report on Monday, April 2nd. Zacks Investment Research lowered shares of Achaogen from a “hold” rating to a “sell” rating in a research report on Monday, February 5th. Mizuho restated a “buy” rating on shares of Achaogen in a research report on Thursday, May 3rd. Finally, Wedbush restated an “outperform” rating and issued a $22.00 price target (down from $28.00) on shares of Achaogen in a research report on Wednesday, February 14th.

In related news, major shareholder Robert W. Duggan bought 20,000 shares of Achaogen stock in a transaction dated Wednesday, February 28th. The shares were bought at an average cost of $10.70 per share, for a total transaction of $214,000.00. Following the completion of the transaction, the insider now owns 5,697,752 shares of the company’s stock, valued at $60,965,946.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Robert W. Duggan bought 527,396 shares of Achaogen stock in a transaction dated Friday, March 2nd. The shares were bought at an average price of $10.31 per share, for a total transaction of $5,437,452.76. Following the completion of the transaction, the insider now directly owns 5,697,752 shares of the company’s stock, valued at approximately $58,743,823.12. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 2,545,730 shares of company stock worth $29,680,700 and have sold 10,989 shares worth $124,967. 7.80% of the stock is currently owned by corporate insiders.

Several hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp lifted its position in shares of Achaogen by 3.6% during the fourth quarter. Bank of New York Mellon Corp now owns 144,843 shares of the biopharmaceutical company’s stock worth $1,555,000 after purchasing an additional 4,999 shares in the last quarter. Swiss National Bank lifted its position in shares of Achaogen by 12.9% during the first quarter. Swiss National Bank now owns 50,000 shares of the biopharmaceutical company’s stock worth $648,000 after purchasing an additional 5,700 shares in the last quarter. TimesSquare Capital Management LLC lifted its position in shares of Achaogen by 0.5% during the fourth quarter. TimesSquare Capital Management LLC now owns 1,367,965 shares of the biopharmaceutical company’s stock worth $14,692,000 after purchasing an additional 6,300 shares in the last quarter. Teachers Advisors LLC lifted its position in shares of Achaogen by 15.0% during the fourth quarter. Teachers Advisors LLC now owns 62,483 shares of the biopharmaceutical company’s stock worth $671,000 after purchasing an additional 8,137 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its position in shares of Achaogen by 34.3% during the third quarter. Wells Fargo & Company MN now owns 33,213 shares of the biopharmaceutical company’s stock worth $530,000 after purchasing an additional 8,483 shares in the last quarter. Institutional investors own 76.88% of the company’s stock.

Achaogen opened at $12.89 on Thursday, MarketBeat.com reports. The stock has a market capitalization of $576.53 million, a price-to-earnings ratio of -4.07 and a beta of 1.02. Achaogen has a 12 month low of $12.89 and a 12 month high of $13.14. The company has a current ratio of 7.01, a quick ratio of 7.01 and a debt-to-equity ratio of 0.24.

Achaogen (NASDAQ:AKAO) last released its quarterly earnings results on Friday, May 4th. The biopharmaceutical company reported ($1.06) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.89) by ($0.17). The firm had revenue of $2.14 million during the quarter, compared to analyst estimates of $1.25 million. Achaogen had a negative net margin of 2,384.08% and a negative return on equity of 97.86%. research analysts predict that Achaogen will post -3.43 earnings per share for the current fiscal year.

Achaogen Company Profile

Achaogen, Inc, a late-stage biopharmaceutical company, focusses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.

Analyst Recommendations for Achaogen (NASDAQ:AKAO)

Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply